The Ophthalmology segment focuses on the research and development of novel therapeutics for retinal diseases and other serious eye conditions. Surrozen is leveraging its expertise in the Wnt pathway to develop targeted antibody-based therapies. Research and development activities include preclinical studies, clinical trials, and the evaluation of biomarkers. The company is currently prioritizing its ophthalmology pipeline with a focus on developing new treatment options for retinopathies. This segment addresses significant unmet medical needs in the treatment of eye diseases, aiming to improve patient outcomes and quality of life. Market positioning is based on the company's unique approach to modulating the Wnt pathway. Future opportunities include expanding the pipeline to address other ophthalmic indications and securing regulatory approvals for its product candidates. Partnerships with companies like Boehringer Ingelheim are key to advancing the development of these therapies. Regulatory and clinical aspects include Phase 1b clinical trials and the pursuit of FDA approval.

The Liver Disease segment is dedicated to developing therapies for liver repair and regeneration. Surrozen's research focuses on utilizing its proprietary antibody-based technologies to modulate the Wnt pathway to stimulate hepatocyte regeneration, improve liver function, and reduce fibrosis. This segment includes preclinical research, clinical trials, and the development of novel drug candidates. The company's lead product candidate, SZN-043, is designed to address liver diseases. The patient impact is significant, as these therapies aim to improve outcomes for patients with liver damage and dysfunction. Market positioning is based on the company's unique approach to modulating the Wnt pathway. Future opportunities include expanding the pipeline to address other liver diseases and securing regulatory approvals for its product candidates. Regulatory and clinical aspects include Phase 1b clinical trials and the pursuit of FDA approval.

The Intestinal Diseases segment focuses on developing therapies for diseases of the intestine. Surrozen is developing SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. Research and development activities include preclinical studies, clinical trials, and the evaluation of biomarkers. The company aims to address significant unmet medical needs in the treatment of intestinal diseases, aiming to improve patient outcomes and quality of life. Market positioning is based on the company's unique approach to modulating the Wnt pathway. Future opportunities include expanding the pipeline to address other intestinal indications and securing regulatory approvals for its product candidates. Regulatory and clinical aspects include clinical trials and the pursuit of FDA approval.